Program final

7th Biennial Workshop on Dystonia and Parkinson’s Disease:

Cellular and molecular targets for novel therapeutics”

Rome, September 18-19, 2019

Nobile Collegio Chimico Farmaceutico, Rome, Italy

Sept. 18

12 p.m. Opening light lunch

12.45 p.m. Welcome from authorities

1.00 p.m. Welcoming remarks: Antonio Pisani, Jan Teller, Bonnie Strauss

1.15-2.15 p.m. Debate 1. Are the clinical features of isolated dystonia the same as those of dystonia in Parkinson disease?

Chair: Alberto Albanese, Joel Perlmutter

Speakers:  Kailash Bhatia, Anthony Lang

2.15-2.30 p.m. Discussion

2.30-3.30 p.m. Session 1. Dystonia and PD: new genes, new therapeutic targets?

(Are gene products leading to discoveries for novel therapeutic agents?)

Chairs: Enza Maria Valente, Rose Goodchild

  • Niccolò Mencacci: New genes for rare hyperkinetic movement disorders: what are we learning about molecular pathophysiology of striatal disorders?
  • Miryam Carecchio – When genetics meet surgery: DBS outcome in genetically-determined dystonia and PD
  • Ellen Hess- Shared and unique pathophysiological features of PD and DOPA-responsive dystonia

 3.30-4.30 Data blitz (selection from 2-3 posters, 3 min presentation)

Chairs: Annarita Bentivoglio, Mariangela Pierantozzi

16.30- adjourn

Sept. 19

 9.00-9.40. Debate 2. Dopamine receptors in dystonia and levodopa-induced dyskinesias: distinct targets?

Chairs: Erwan Bezard

Speakers: David G. Standaert, Paola Bonsi

9.40-10.00. Discussion

Session 2

10.00-11.00 a.m. Novel cellular and molecular targets (do dystonia targets apply for PD?)

Chairs: Fabio Blandini, Buz Jinnah

  • Nicole Calakos- eIF2alpha signaling in dystonia
  • Pedro Gonzalez Alegre- ERK signaling in the striatum: a point of convergence for hyperkinetic disorders?
  • Fabrizio Gardoni – Differential modifications of AMPA and NMDA receptor subunits at striatal synapses in PD and dystonia 

Coffee break

11.30 a.m.- 12.30 p.m. Session 3. Novel technologies for dystonia and PD research

Chairs: Paolo Calabresi, Cris Bragg

  • Philipp Capetian- Patient-derived vs. isogenic neural stem cell models
  • Giuseppe Sciamanna- Role of Globus Pallidus in Dystonia: Optogenetic strategies to unveil the altered neural circuits
  • Lilian Cruz- CRISPR/Cas9 for allele-specific editing in DYT1 iPSCs



2.30-3.30 p.m. Session 4: Molecular Targets for dystonia and PD: Clues from treatable inherited disorders. 

Chairs: Marie Vidailhet, Vincenzo Leuzzi

  • Vincenzo Leuzzi- Parkinsonism in Children
  • Emmanuel Roze- Triheptanoin for the treatment of Brain energy deficit: from Glut1 deficiency to other movement disorders
  • Thomas Klopstock – Heavy metals: possible therapy with chelating agents

3.30-4 p.m. Discussion

Coffee break

Round-table. Novel drugs for dystonia and PD

Chairs: Erwan Bezard, Alessandro Stefani, Nicola B. Mercuri, Jan Teller, Tom Salt, Mitchell Brin

6 p.m. Adjourn

 Scientific Committee (B. Jinnah, N.B. Mercuri, A. Pisani (Chair), D.G. Standaert, J. Teller)